Pfizer announced today that it has submitted a Biologics License Application to the FDA for its next-generation mRNA vaccine targeting multiple respiratory viruses. The combination vaccine is designed to protect against COVID-19 variants, influenza A, and respiratory syncytial virus in a single dose.
Clinical trial data from the Phase 3 study showed the vaccine achieved strong immune responses across all three viral targets, with an overall efficacy rate of 78 percent. Side effects were consistent with those observed in earlier mRNA vaccines, including mild injection site pain and fatigue.
Industry analysts say the combination vaccine could simplify the annual vaccination process for millions of Americans. If approved, Pfizer expects the vaccine to be available by the fall 2026 respiratory season.
